On May 12, 2025 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported that data from its OPTIMIZE-1 clinical trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Alligator Bioscience, MAY 12, 2025, View Source [SID1234652861]). The presentation, titled "Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer," will take place during the Developmental Therapeutics—Immunotherapy session, focusing on tissue-based biomarkers. The presentation will be available at Poster Board #271.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The ASCO (Free ASCO Whitepaper) Annual Meeting is the premier event for advancing clinical oncology, where professionals connect and collaborate. It also offers valuable business development opportunities, supporting Alligator’s efforts to expand mitazalimab’s potential and explore strategic collaborations.
Abstract Details:
• Title: Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer
• First Author: Philippe Cassier
• Date and time: 2nd June 2025, 1.30 p.m. – 4:30 p.m CDT.
• Session Title: Developmental Therapeutics—Immunotherapy
• Sub Track: Tissue-Based Biomarkers
• Abstract Number: 2624
• Poster Board Number: 271
• Abstract link